A new Swedish cell and gene therapy company, Elicera Therapeutics, has announced that it has completed its first share issue and secured 13.2 MSEK in financing.
The company is based on research by professor Magnus Essand’s research group at Uppsala University and will focus on CAR T cells and oncolytic viruses.
Four different drug candidates
The company has developed four different drug candidates, in different development phases, and it has also initiated its first clinical study with the oncolytic virus Advince for treatment of neuroendocrine tumors. The drug candidates have shown promising pre-clinical results in several vivo cancer models, states the company, and so far clinical data from the oncolytic treatment of neuroendocrine tumors has shown that it is safe and has promising effects.
Thanks to financial contribution from Cancerfonden Elicera now aims to start GMP production of CAR T cells before a clinical trial (planned to start during 2022) for treatment of blood cancer.
Jamal El-Mosleh is announced as Elicera’s CEO.
Photo of Magnus Essand and Di Yu, Uppsala University